This article was originally published in The Tan Sheet
Consumer Healthcare sales for the third quarter of fiscal 2006 (ended March 25) were up nearly 10% to $241.2 mil. compared to $219.7 mil. a year ago, Perrigo announces April 27. The increase occurred despite a $26 mil. decrease in sales of cough/cold products containing pseudoephedrine. The impact of pseudoephedrine declines was offset by the addition of topical product sales of $16 mil. from the recently acquired Israeli firm Agis. Effects from lower cough/cold sales also were offset by new product gains in smoking cessation and higher vitamin sales, Perrigo states. "Because of the new products, fourth quarter profitability should be in line with historical levels despite increased costs for the large number of cough/cold product reformulations," Perrigo Chairman, President and CEO David Gibbons stated. Net sales for the third quarter were up 51% to $332.3 mil. from $220.1 mil. last year...
You may also be interested in...
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.